NCT03297359 (WAVe) is a Phase 2 clinical trial of Dalteparin in Cancer, sponsored by Ottawa Hospital Research Institute.

Who is sponsoring NCT03297359?

NCT03297359 is sponsored by Ottawa Hospital Research Institute.

What drugs are being tested in NCT03297359?

Interventions in NCT03297359: Dalteparin.

What condition does NCT03297359 study?

NCT03297359 studies Cancer, Venous Thromboembolism, Obesity.

Is NCT03297359 still recruiting?

NCT03297359 is currently terminated. Last updated 23 January 2024.

Last reviewed 2024-01-23 · How we verify

NCT03297359: WAVe

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism

Terminated Phase 2 Last updated 23 January 2024

What this trial tests

Phase 2 trial testing Dalteparin in Cancer in 92 participants. Terminated before completion.

Timeline

21 March 2018

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	Ottawa Hospital Research Institute
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	92
Start date	21 March 2018
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	5 locations across Canada

Drugs / interventions tested

Dalteparin

Conditions studied

Cancer — all drugs for Cancer →
Venous Thromboembolism — all drugs for Venous Thromboembolism →
Obesity — all drugs for Obesity →

Sponsor

Ottawa Hospital Research Institute

Who can join

18 and older, any sex, with Cancer or Venous Thromboembolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cancer patients that develop blood clots are treated with low molecular weight heparin injections (LMWH). One kind of these LMWHs, dalteparin, has its dose determined based on a patient's weight using a formula of 200 international units (IU) per kilogram (kg). The current dosing of dalteparin approved by Health Canada has a maximum daily dose of 18 000 IU/day which is weight-adjusted for patients up to 90 kg. Any patient weighing more than 90 kg would take the same dosage regardless of their weight. The aim of this study is to assess the safety of using weight-adjusted dalteparin in cancer-associated venous thromboembolism patients that weigh more than 90 kg.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

What's new in the prevention and treatment of cancer-associated thrombosis?
Kimpton M, Carrier M. · · 2019 · cited 2× · PMID 31808858 · DOI 10.1182/hematology.2019000023
A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism-The WAVe Study.
Wang TF, Yeo E, Gross PL, Séguin C, et al · · 2026 · cited 1× · PMID 41211763 · DOI 10.1002/ajh.70127

Verify or expand the search:

Other trials of Dalteparin

Trials testing the same drug.

NCT06628778 — Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids · Phase 3 · not yet recruiting
NCT05171075 — A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE · Phase 3 · terminated
NCT04850378 — Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome · Phase 1, PHASE2 · completed
NCT03139487 — A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral · Phase 2 · unknown
NCT03045406 — Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer · Phase 3 · completed

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Ottawa Hospital Research Institute trials

Trials by the same sponsor.

NCT07464080 — Advanced Brain Imaging-TKA (fMRI-TKA) · NA · recruiting
NCT07171567 — Vacuum Therapy for the Treatment of Penile Numbness/Sensory Changes · EARLY_PHASE1 · recruiting
NCT07058025 — Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants · Phase 2 · not yet recruiting
NCT07177833 — Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease · Phase 1 · recruiting
NCT06929767 — Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotic · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03297359 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ottawa Hospital Research Institute
Last refreshed: 23 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03297359.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing